Please use this identifier to cite or link to this item: http://hdl.handle.net/10668/2498
Título : First month prednisone dose predicts prednisone burden during the following 11 months: an observational study from the RELES cohort.
Autor : Ruiz-Irastorza, G
Garcia, M
Espinosa, G
Caminal, L
Mitjavila, F
González-León, R
Sopeña, B
Canora, J
Villalba, M V
Rodríguez-Carballeira, M
López-Dupla, J M
Callejas, J L
Castro, A
Tolosa, C
Sánchez-García, M E
Pérez-Conesa, M
Navarrete-Navarrete, N
Rodríguez, A P
Herranz, M T
Pallarés, L
Filiación: [Ruiz-Irastorza,G; Garcia,M] Autoimmune Diseases Research Unit, Department of Internal Medicine, BioCruces Health Research Institute, Hospital Universitario Cruces, University of the Basque Country, Barakaldo, Bizkaia, Spain. [Espinosa,G] Department of Autoimmune Diseases, Hospital Clinic, Barcelona, Spain. [Caminal,L] Department of Internal Medicine, Hospital Universitario Central de Asturias, Oviedo, Asturias , Spain. [Mitjavila,F] Autoimmune Diseases Unit, Department of Internal Medicine, Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain. [González-León,R] Department of Internal Medicine , Hospital Universitario Virgen del Rocío, Sevilla, Spain. [Sopeña,B] Department of Internal Medicine, Complejo Hospitalario Universitario de Vigo, Pontevedra, Vigo , Spain. [Canora,J] Department of Internal Medicine, Hospital Universitario Fuenlabrada, Fuenlabrada, Madrid , Spain. [Villalba,MV] Department of Internal Medicine, Hospital General Universitario Gregorio Marañón, Madrid, Spain. [Rodríguez-Carballeira,M] Department of Internal Medicine, Hospital Universitario Mutua de Terrasa, Barcelona, Spain. [López-Dupla,JM] Department of Internal Medicine, Hospital Universitario Joan XXIII, Tarragona, Spain. [Callejas,JL] Department of Internal Medicine, Hospital Universitario San Cecilio, Granada, Spain. [Castro,A] Department of Internal Medicine, Hospital Universitario Sant Joan de Reus, Reus, Tarragona , Spain. [Tolosa,C] Department of Internal Medicine, Corporació Sanitària Parc Taulí, Sabadell, Barcelona, Spain. [Sánchez-García,ME] Department of Internal Medicine, Autoimmune Diseases Unit, Hospital Universitario Reina Sofía , Córdoba, Spain. [Pérez-Conesa,M] Department of Internal Medicine, Hospital Universitario Miguel Servet, Zaragoza, Spain. [Navarrete-Navarrete,N] Department of Internal Medicine , Hospital Universitario Virgen de las Nieves, Granada, Spain. [Rodríguez,AP] Department of Internal Medicine, Complejo Hospitalario Universitario de Ourense, Ourense, Spain. [Herranz,MT] Department of Internal Medicine, Hospital J.M. Morales Meseguer, Murcia, Spain. [Pallarés,L] Department of Internal Medicine, Hospital Universitario Son Espases, Palma de Mallorca, Islas Baleares, Spain.
Grupo de Investigación: RELES, Autoimmune Diseases Study Group (GEAS)
Palabras clave : Antimaláricos
Glucocorticoides
Humanos
Inmunosupresores
Lupus eritematoso discoide
Lupus eritematoso sistémico
Nefritis lúpica
Metilprednisolona
Prednisona
Pulso arterial
MeSH: Medical Subject Headings::Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Antiparasitic Agents::Antiprotozoal Agents::Antimalarials
Medical Subject Headings::Chemicals and Drugs::Hormones, Hormone Substitutes, and Hormone Antagonists::Hormones::Adrenal Cortex Hormones::Glucocorticoids
Medical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans
Medical Subject Headings::Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Physiological Effects of Drugs::Immunologic Factors::Immunosuppressive Agents
Medical Subject Headings::Diseases::Skin and Connective Tissue Diseases::Connective Tissue Diseases::Lupus Erythematosus, Cutaneous::Lupus Erythematosus, Discoid
Medical Subject Headings::Diseases::Skin and Connective Tissue Diseases::Connective Tissue Diseases::Lupus Erythematosus, Systemic
Medical Subject Headings::Diseases::Skin and Connective Tissue Diseases::Connective Tissue Diseases::Lupus Erythematosus, Systemic::Lupus Nephritis
Medical Subject Headings::Chemicals and Drugs::Polycyclic Compounds::Steroids::Pregnanes::Pregnadienes::Pregnadienetriols::Prednisolone::Methylprednisolone
Medical Subject Headings::Chemicals and Drugs::Polycyclic Compounds::Steroids::Pregnanes::Pregnadienes::Pregnadienediols::Prednisone
Medical Subject Headings::Phenomena and Processes::Circulatory and Respiratory Physiological Phenomena::Cardiovascular Physiological Phenomena::Hemodynamics::Pulse
Fecha de publicación : 16-Aug-2016
Editorial : BMJ Publishing Group
Cita Bibliográfica: Ruiz-Irastorza G, Garcia M, Espinosa G, Caminal L, Mitjavila F, González-León R, et al. First month prednisone dose predicts prednisone burden during the following 11 months: an observational study from the RELES cohort. Lupus Sci Med. 2016; 3(1):e000153
Abstract: AIM To study the influence of prednisone dose during the first month after systemic lupus erythematosus (SLE) diagnosis (prednisone-1) on glucocorticoid burden during the subsequent 11 months (prednisone-2-12). METHODS 223 patients from the Registro Español de Lupus Eritematoso Sistémico inception cohort were studied. The cumulative dose of prednisone-1 and prednisone-2-12 were calculated and recoded into a four-level categorical variable: no prednisone, low dose (up to 7.5 mg/day), medium dose (up to 30 mg/day) and high dose (over 30 mg/day). The association between the cumulative prednisone-1 and prednisone-2-12 doses was tested. We analysed whether the four-level prednisone-1 categorical variable was an independent predictor of an average dose >7.5 mg/day of prednisone-2-12. Adjusting variables included age, immunosuppressives, antimalarials, methyl-prednisolone pulses, lupus nephritis and baseline SLE Disease Activity Index (SLEDAI). RESULTS Within the first month, 113 patients (51%) did not receive any prednisone, 24 patients (11%) received average low doses, 46 patients (21%) received medium doses and 40 patients (18%) received high doses. There was a strong association between prednisone-1 and prednisone-2-12 dose categories (p<0.001). The cumulative prednisone-1 dose was directly associated with the cumulative prednisone-2-12 dose (p<0.001). Compared with patients on no prednisone, patients taking medium (adjusted OR 5.27, 95% CI 2.18 to 12.73) or high-dose prednisone-1 (adjusted OR 10.5, 95% CI 3.8 to 29.17) were more likely to receive prednisone-2-12 doses of >7.5 mg/day, while patients receiving low-dose prednisone-1 were not (adjusted OR 1.4, 95% CI 0. 0.38 to 5.2). If the analysis was restricted to the 158 patients with a baseline SLEDAI of ≥6, the model did not change. CONCLUSION The dose of prednisone during the first month after the diagnosis of SLE is an independent predictor of prednisone burden during the following 11 months.
Descripción : Journal Article;
URI: http://hdl.handle.net/10668/2498
Versión del editor : http://lupus.bmj.com/content/3/1/e000153
DOI: 10.1136/lupus-2016-000153
ISSN : 2053-8790 (Online)
Appears in Collections:01- Artículos - Hospital Virgen del Rocío
01- Artículos - Hospital Reina Sofía
01- Artículos - Complejo Hospitalario Universitario de Granada

Files in This Item:
File Description SizeFormat 
RuizIrastorza_FirstMonthPrednisone.pdfArtículo publicado507,83 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons